Abstract

CURCIO, Pasqualina Curcio. Incentivos y desincentivos de la industria farmacéutica privada para la I+D de nuevos medicamentos. Cad. Saúde Pública [online]. 2008, vol.24, n.10, pp. 2363-2375. ISSN 0102-311X.  http://dx.doi.org/10.1590/S0102-311X2008001000017.

The authors present a model with factors that influence research and development decisions by the pharmaceutical industry: risk of disease transmission and possibility of control; case-fatality and the presence of cure or treatments; income; number of persons who demand the medicine; and opportunity costs for the company. Companies tend to invest in markets with inelastic demand (highly contagious diseases with no possibility of controlling transmission and/or very lethal diseases without treatment) and/or where there is a large population or high per capita income. Companies tend not to invest in markets where marginal costs exceed marginal income, particularly when costs increase permanently as a consequence of rising opportunity costs generated by foregoing profit in other markets. In such cases, policies to subsidize R&D are not effective, and policies must be orientated towards strengthening basic and applied research by public institutions.

Keywords : Pharmaceutical Industry; Health Policies; Pharmaceutical Preparations; Motivation.